Cargando…

Review of pyronaridine anti-malarial properties and product characteristics

Pyronaridine was synthesized in 1970 at the Institute of Chinese Parasitic Disease and has been used in China for over 30 years for the treatment of malaria. Pyronaridine has high potency against Plasmodium falciparum, including chloroquine-resistant strains. Studies in various animal models have sh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Croft, Simon L, Duparc, Stephan, Arbe-Barnes, Sarah J, Craft, J Carl, Shin, Chang-Sik, Fleckenstein, Lawrence, Borghini-Fuhrer, Isabelle, Rim, Han-Jong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483207/ https://www.ncbi.nlm.nih.gov/pubmed/22877082 http://dx.doi.org/10.1186/1475-2875-11-270

Ejemplares similares

Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials
por: Duparc, Stephan, et al.
Publicado: (2013)

Pharmacokinetic Interaction between Pyronaridine-Artesunate and Metoprolol
por: Morris, Carrie A., et al.
Publicado: (2014)

Population Pharmacokinetics of Pyronaridine in Pediatric Malaria Patients
por: Ayyoub, Amal, et al.
Publicado: (2016)

Drug-Drug Interaction Analysis of Pyronaridine/Artesunate and Ritonavir in Healthy Volunteers
por: Morris, Carrie A., et al.
Publicado: (2012)

Pyronaridine-Artesunate versus Chloroquine in Patients with Acute Plasmodium vivax Malaria: A Randomized, Double-Blind, Non-Inferiority Trial
por: Poravuth, Yi, et al.
Publicado: (2011)

Efficacy, Safety and Tolerability of Pyronaridine-artesunate in Asymptomatic Malaria-infected Individuals: a Randomized Controlled Trial
por: Dabira, Edgard D, et al.
Publicado: (2021)

Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration
por: Morris, Carrie A, et al.
Publicado: (2011)

Effectiveness of pyronaridine-artesunate against Plasmodium malariae, Plasmodium ovale spp, and mixed-Plasmodium infections: a post-hoc analysis of the CANTAM-Pyramax trial
por: Groger, Mirjam, et al.
Publicado: (2022)

Efficacy and Safety of Pyronaridine–Artesunate for the Treatment of Uncomplicated Plasmodium falciparum and Plasmodium vivax Malaria in Myanmar
por: Han, Kay Thwe, et al.
Publicado: (2020)

Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial
por: Kayentao, Kassoum, et al.
Publicado: (2012)

Pyronaridine–artesunate real-world safety, tolerability, and effectiveness in malaria patients in 5 African countries: A single-arm, open-label, cohort event monitoring study
por: Tona Lutete, Gaston, et al.
Publicado: (2021)

Global gene expression profiling of Plasmodium falciparum in response to the anti-malarial drug pyronaridine
por: Kritsiriwuthinan, Kanyanan, et al.
Publicado: (2011)

In vitro activity of pyronaridine against Plasmodium falciparum and comparative evaluation of anti-malarial drug susceptibility assays
por: Kurth, Florian, et al.
Publicado: (2009)

Similarly efficacious anti-malarial drugs SJ733 and pyronaridine differ in their ability to remove circulating parasites in mice
por: SheelaNair, Arya, et al.
Publicado: (2022)

Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial
por: Sagara, Issaka, et al.
Publicado: (2016)

Plasmodium vivax in Children: Hidden Burden and Conspicuous Challenges, a Narrative Review
por: Drysdale, Myriam, et al.
Publicado: (2022)

Community health workers in clinical research at the example of a phase IIIb/ IV antimalarial drug trial conducted in five African countries
por: Groger, Mirjam, et al.
Publicado: (2023)

New developments in anti-malarial target candidate and product profiles
por: Burrows, Jeremy N., et al.
Publicado: (2017)

First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials
por: Moehrle, Joerg J, et al.
Publicado: (2013)

Erratum to: New developments in anti-malarial target candidate and product profiles
por: Burrows, Jeremy N., et al.
Publicado: (2017)

Optimal dose finding for novel antimalarial combination therapy*
por: Duparc, S, et al.
Publicado: (2012)

Transporter Inhibition Profile for the Antivirals Tilorone, Quinacrine and Pyronaridine
por: Vignaux, Patricia A., et al.
Publicado: (2023)

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria
por: Pryce, Joseph, et al.
Publicado: (2019)

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria
por: Pryce, Joseph, et al.
Publicado: (2022)

Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials
por: Carter, Nick, et al.
Publicado: (2011)

Pyronaridine tetraphosphate is an efficacious antiviral and anti-inflammatory active against multiple highly pathogenic coronaviruses
por: Ardanuy, Jeremy, et al.
Publicado: (2023)

Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria
por: Bukirwa, Hasifa, et al.
Publicado: (2014)

Multinormal in vitro distribution of Plasmodium falciparum susceptibility to piperaquine and pyronaridine
por: Pascual, Aurélie, et al.
Publicado: (2015)

Evidence for in vitro and in vivo activity of the antimalarial pyronaridine against Schistosoma
por: Koehne, Erik, et al.
Publicado: (2021)

Environmentally Responsible and Cost-Effective Synthesis of the Antimalarial Drug Pyronaridine
por: Kincaid, Joseph R. A., et al.
Publicado: (2022)

Pyronaridine: a review of its clinical pharmacology in the treatment of malaria
por: Chu, Wan-Yu, et al.
Publicado: (2023)

Injectable anti-malarials revisited: discovery and development of new agents to protect against malaria
por: Macintyre, Fiona, et al.
Publicado: (2018)

Evaluation of the QT effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the treatment of uncomplicated malaria
por: Darpo, Borje, et al.
Publicado: (2015)

Pharmacokinetic Interactions between Primaquine and Pyronaridine-Artesunate in Healthy Adult Thai Subjects
por: Jittamala, Podjanee, et al.
Publicado: (2014)

Psychiatric effects of malaria and anti-malarial drugs: historical and modern perspectives
por: Nevin, Remington L., et al.
Publicado: (2016)

Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection
por: Lane, Thomas R., et al.
Publicado: (2019)

Correction: Evidence for in vitro and in vivo activity of the antimalarial pyronaridine against Schistosoma
por: Koehne, Erik, et al.
Publicado: (2022)

Correlation between anti-malarial and anti-haemozoin activities of anti-malarial compounds
por: Tam, Dao Ngoc Hien, et al.
Publicado: (2020)

Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects
por: Tan, Beesan, et al.
Publicado: (2009)

Plasmodium falciparum gametocyte dynamics after pyronaridine–artesunate or artemether–lumefantrine treatment
por: Roth, Johanna M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_huevpg47enp5v2kg8oqgfumt9o